Voltar
Artigo Revisado por pares
BIBTEX RIS

Biological Effects of Disruption of the Tissue‐Type Plasminogen Activator, Urokinase‐Type Plasminogen Activator, and Plasminogen Activator Inhibitor‐1 Genes in Mice a

1994; Wiley; Volume: 748; Issue: 1 Linguagem: Inglês

10.1111/j.1749-6632.1994.tb17333.x

ISSN

1749-6632

Autores

Peter Carmeliet, Ann Bouché, C. DE CLERCQ, Sara Janssen, Saskia Pollefeyt, Sabine Wyns, Richard C. Mulligan, D Collen,

Tópico(s)

Meat and Animal Product Quality

Resumo

Annals of the New York Academy of SciencesVolume 748, Issue 1 p. 367-381 Biological Effects of Disruption of the Tissue-Type Plasminogen Activator, Urokinase-Type Plasminogen Activator, and Plasminogen Activator Inhibitor-1 Genes in Micea P. CARMELIET, P. CARMELIET Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, Belgium Whitehead Institute of Biomedical Research and Department of Biology Massachusetts Institute of Technology Cambridge, MassachusettsSearch for more papers by this authorA. BOUCHÉ, A. BOUCHÉ Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, BelgiumSearch for more papers by this authorC. DE CLERCQ, C. DE CLERCQ Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, BelgiumSearch for more papers by this authorS. JANSSEN, S. JANSSEN Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, BelgiumSearch for more papers by this authorS. POLLEFEYT, S. POLLEFEYT Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, BelgiumSearch for more papers by this authorS. WYNS, S. WYNS Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, BelgiumSearch for more papers by this authorR. C. MULLIGAN, R. C. MULLIGAN Whitehead Institute of Biomedical Research and Department of Biology Massachusetts Institute of Technology Cambridge, MassachusettsSearch for more papers by this authorD. COLLEN, Corresponding Author D. COLLEN Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, BelgiumdAuthor to whom correspondence should be addressed.Search for more papers by this author P. CARMELIET, P. CARMELIET Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, Belgium Whitehead Institute of Biomedical Research and Department of Biology Massachusetts Institute of Technology Cambridge, MassachusettsSearch for more papers by this authorA. BOUCHÉ, A. BOUCHÉ Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, BelgiumSearch for more papers by this authorC. DE CLERCQ, C. DE CLERCQ Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, BelgiumSearch for more papers by this authorS. JANSSEN, S. JANSSEN Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, BelgiumSearch for more papers by this authorS. POLLEFEYT, S. POLLEFEYT Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, BelgiumSearch for more papers by this authorS. WYNS, S. WYNS Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, BelgiumSearch for more papers by this authorR. C. MULLIGAN, R. C. MULLIGAN Whitehead Institute of Biomedical Research and Department of Biology Massachusetts Institute of Technology Cambridge, MassachusettsSearch for more papers by this authorD. COLLEN, Corresponding Author D. COLLEN Center for Molecular and Vascular Biology University of Leuven Herestraat 44 B-3000 Leuven, BelgiumdAuthor to whom correspondence should be addressed.Search for more papers by this author First published: January 1994 https://doi.org/10.1111/j.1749-6632.1994.tb17333.xCitations: 43 a P. Carmeliet is a research associate of the Belgian National Fund of Scientific Research (NFWO). This work was supported by the Belgian "Instituut voor Wetenschap en Technologie" (PC, DC), the Belgian "InterUniversitaire AttractiePolen," and the National Institute of Health (Grant number POIHL 41484 to RCM). This overview is based on three reports, published elsewhere,1–3 and on additional unpublished information. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Carmeliet, P., L. Kieckens, L. Schoonjans, B. Ream, A. van Nuffelen, G. Prendergast, M. Cole, R. Bronson, D. Collen & R. C. Mulligan. 1993. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J. Clin. Invest. 92: 2746–2755. PubMedWeb of Science®Google Scholar 2 Carmeliet, P., J. M. Stassen, L. Schoonjans, B. Ream, J. J. van den Oord, M. de Mol, R. C. Mulligan & D. Collen. 1993. Plasminogen activator inhibitor-1 gene deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J. Clin. Invest. 92: 2756. PubMedWeb of Science®Google Scholar 3 Carmeliet, P., L. Schoonjans, L. Kieckens, B. Ream, J. Degen, R. Bronson, R. DeVos, J. J. van den Oord, D. Collen & R. C. Mulligan. 1994 Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419–424. PubMedWeb of Science®Google Scholar 4 Astrup, T. 1978. In Progress in Chemical Fibrinolysis and Thrombolysis. P. C. Desnoyers, Eds. Raven Press. New York , N.Y . Google Scholar 5 Collen, D. & H. R. Lijnen. 1991 Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78: 3114–3124. PubMedWeb of Science®Google Scholar 6 Vassalli, J. D., A. P. Sappino & D. Belin. 1991. The plasminogen activator/plasmin system. J. Clin. Invest. 88: 1067–1072. 10.1172/JCI115405 CASPubMedWeb of Science®Google Scholar 7 Schneiderman, J. & D. J. Loskutoff. 1991. Plasminogen activator inhibitors. Trends Cardiovasc. Med. 1: 99–102. 10.1016/1050-1738(91)90001-U CASPubMedWeb of Science®Google Scholar 8 Nillsson, I. M., H. Ljunger & L. Tengborn. 1985. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br. Med. J. 290: 1453–1455. Google Scholar 9 Juhan-Vague, I. & D. Collen. 1992. On the role of coagulation and fibrinolysis in atherosclerosis. Ann. Epidemiol. 2: 427–438. PubMedGoogle Scholar 10 Blasi, F., J-D. Vassalli & K. Dano. 1987. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol. 104: 801–804. PubMedWeb of Science®Google Scholar 11 Saksela, O. & D. B. Rifkin. 1988. Cell-associated plasminogen activation: regulation and physiological function. Annu. Rev. Cell Biol. 4: 93–126. 10.1146/annurev.cb.04.110188.000521 CASPubMedWeb of Science®Google Scholar 12 Danø, K., P. A. Andreasen, J. Grøndahl-Hansen, P. Kristensen, L. S. Nielsen & L. Skriver. 1985. Plasminogen activators, tissue degradation, and cancer. Adv. Canc. Res. 44: 139–266. 10.1016/S0065-230X(08)60028-7 PubMedWeb of Science®Google Scholar 13 Fay, W. P., A. D. Shapiro, J. L. Shih, R. R. Schleef & D. Ginsburg. 1992. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 to a frame-shift mutation. N. Engl. J. Med. 327: 1729–1733. PubMedWeb of Science®Google Scholar 14 Stassen, J. M., I. Vanlinthout, H. R. Lijnen & D. Collen. 1990 A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents. 4(Suppl. 2): 15–21. Google Scholar 15 Unkeless, J. C., S. Gordon & E. Reich. 1974. Secretion of plasminogen activator by stimulated macrophages. J. Exp. Med. 139: 834–850. PubMedWeb of Science®Google Scholar 16 Freyria, A. M., J. Paul, J. Belleville, P. Broyer & R. Eloy. 1991. Rat peritoneal macrophage procoagulant and fibrinolytic activities. An expression of the local inflammatory response. Comp. Biochem. Physiol. 99: 517–524. PubMedWeb of Science®Google Scholar 17 Baker, M. S., P. Bleakley, G. C. Woodrow & W. F. Doe. 1990. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-1 and subsequent effects on extracellular matrix degradation. Cancer Res. 50: 4676–4684. PubMedWeb of Science®Google Scholar 18 Lala, P. K. & C. H. Graham. 1990. Mechanisms of trophoblast invasiveness and their control: the role of proteases and protease inhibitors. Cancer Metastasis Rev. 9: 369–379. PubMedWeb of Science®Google Scholar 19 Tomooka, S., W. A. Border, B. C. Marshall & N. A. Noble. 1992. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int. 42: 1462–1469. PubMedWeb of Science®Google Scholar 20 Rickles, R. J., A. L. Darrow & S. J. Strickland. 1988. Molecular cloning of complementary DNA to mouse tissue plasminogen activator mRNA and its expression during F9 teratocarcinoma cell differentiation. J. Biol. Chem. 263: 392–395. Google Scholar 21 Belin, D., J. D. Vassalli, C. Combepine, F. Godeau, Y. Nagamine, E. Reich, H. P. Kocher & R. M. Duvoisin. 1985. Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator. Eur. J. Biochem. 148: 225–232. PubMedWeb of Science®Google Scholar 22 Vassalli, J. D., J. M. Dayer, A. Wohlwend & D. Belin. 1984. Concomitant secretion of prourekinase and of a plasminogen activator–specific inhibitor by cultured human monocytes-macrophages. J. Exp. Med. 159: 1653–1668. PubMedWeb of Science®Google Scholar Citing Literature Volume748, Issue1Atherosclerosis III: Recent Advances in Atherosclerosis ResearchJanuary 1994Pages 367-381 ReferencesRelatedInformation

Referência(s)